ATR:NYE-AptarGroup Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 155.94

Change

0.00 (0.00)%

Market Cap

USD 4.78B

Volume

0.26M

Analyst Target

USD 125.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AptarGroup, Inc., is a solution provider of packaging delivery solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+3.13 (+1.83%)

USD 50.27B
ALC Alcon AG

+0.18 (+0.21%)

USD 44.43B
RMD ResMed Inc

+3.38 (+1.39%)

USD 36.90B
BAX Baxter International Inc

+0.75 (+2.49%)

USD 16.25B
SOLV Solventum Corp.

+1.72 (+2.43%)

USD 12.82B
AVTR Avantor Inc

+0.46 (+3.62%)

USD 9.14B
STVN Stevanato Group SpA

+0.53 (+2.38%)

USD 6.09B
TFX Teleflex Incorporated

+2.18 (+1.80%)

USD 5.34B
BLCO Bausch + Lomb Corp

+0.51 (+4.52%)

USD 4.00B
WRBY Warby Parker Inc

+0.78 (+3.94%)

USD 2.41B

ETFs Containing ATR

NBSM Neuberger Berman ETF Trus.. 2.57 % 0.00 %

+0.45 (+1.88%)

USD 0.17B
FCUL:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.74% 68% D+ 53% F
Dividend Return 0.29% 38% F 9% A-
Total Return -0.45% 68% D+ 52% F
Trailing 12 Months  
Capital Gain 5.30% 74% C 63% D
Dividend Return 0.91% 67% D+ 19% F
Total Return 6.21% 74% C 57% F
Trailing 5 Years  
Capital Gain 38.55% 80% B- 55% F
Dividend Return 6.65% 83% B 15% F
Total Return 45.21% 87% B+ 47% F
Average Annual (5 Year Horizon)  
Capital Gain 4.14% 74% C 53% F
Dividend Return 5.28% 79% B- 49% F
Total Return 1.14% 67% D+ 27% F
Risk Return Profile  
Volatility (Standard Deviation) 19.65% 68% D+ 50% F
Risk Adjusted Return 26.87% 89% A- 45% F
Market Capitalization 4.78B 67% D+ 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.10 75% 24%
Price/Book Ratio 4.09 27% 22%
Price / Cash Flow Ratio 16.12 40% 23%
Price/Free Cash Flow Ratio 14.44 71% 30%
Management Effectiveness  
Return on Equity 15.05% 93% 77%
Return on Invested Capital 11.55% 87% 72%
Return on Assets 7.13% 93% 87%
Debt to Equity Ratio 27.84% 67% 74%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector